The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin

Basit Öğe Kaydı
dc.contributor.authorTuzcu, A
dc.contributor.authorBahceci, M
dc.contributor.authorYilmaz, E
dc.contributor.authorBahceci, S
dc.contributor.authorTuzcu, S
dc.date.accessioned2024-04-24T16:24:10Z
dc.date.available2024-04-24T16:24:10Z
dc.date.issued2004
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Patients with end-stage renal disease (ESRD) are known to have insulin resistance. Treatment with EPO is associated with improvement in insulin sensitivity in uremic patients. The aim of this study was to compare insulin sensitivity and pancreatic B cell function in adult non-diabetic uremic hemodialysis patients treated with or without rHuEPO. Subjects and Methods: Three groups of subjects were included to the study: hemodialysis patients treated with rHuEPO [EPO(+) group] or without rHuEPO [EPO(-) group], and healthy controls. Anthropometrical parameters, lipid levels, fasting glucose and insulin levels were measured in all subjects. Homeostasis Model Assessment (HOMA) was used to compare insulin sensitivity. ANOVA, independent t-test, and Pearson correlation were used for statistical analysis. Results: Mean insulin level of control group (20.04 +/- 7.2 pmol/l) was significantly lower than EPO(+) group (p<0.04) and EPO(-) group (p<0.0001). HOMA-(%B) levels in the EPO(+) group were significantly lower than in the EPO(-) group (106 +/- 42, 140 +/- 63 respectively, p<0.02). HOMA(%B) levels in the control group (66 17) were significantly lower than in the EPO(+) and EPO(-) group (p<0.005 an p<0. respectively). HOMA-(%S) levels in the EPO(+) groups was significantly higher than in the EPO(-) group (91 +/- 40, 56 +/- 26, respectively; p<0.01). HOMA-(%S) levels of control group (125 +/- 24) was significantly higher than EPO(+) and EPO(-) groups (p<0.02, p<0.0001 respectively). We found a positive correlation between duration of erythropoietin treatment and insulin sensitivity (r = 0.484, p<0.002). Conclusions: Firstly, patients treated with EPO are insulin sensitive compared to patients not treated with EPO. Secondly, duration of erythropoietin treatment is positively correlated with insulin sensitivity in hemodialysis patients.en_US
dc.identifier.doi10.1055/s-2004-826021
dc.identifier.endpage720en_US
dc.identifier.issn0018-5043
dc.identifier.issue10en_US
dc.identifier.pmid15523598
dc.identifier.scopus2-s2.0-8444233582
dc.identifier.scopusqualityQ2
dc.identifier.startpage716en_US
dc.identifier.urihttps://doi.org/10.1055/s-2004-826021
dc.identifier.urihttps://hdl.handle.net/11468/16551
dc.identifier.volume36en_US
dc.identifier.wosWOS:000225074600011
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherGeorg Thieme Verlag Kgen_US
dc.relation.ispartofHormone and Metabolic Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEpoen_US
dc.subjectHemodialysisen_US
dc.subjectHoma-(%B)en_US
dc.subjectHoma-(%S)en_US
dc.subjectInsulinen_US
dc.subjectUremiaen_US
dc.titleThe comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietinen_US
dc.titleThe comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu